Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $399

Benzinga Newsdesk www.benzinga.com Positive 76.3%

Neg 0% Neu 0% Pos 76.3%

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $396 to $399.